All times are shown in CEST

8:30 am Chairs Opening Remarks

8:45 am Whole Framome Cancer vaccination


• Discovery of the full potential of frameshift neoantigens as targets of cancer immunotherapy
• Personalized cancer immunotherapy using Framome neoantigen vaccines

9:15 am A Personal Antigen Selection Calculator (PASCal) for the Design of Off-The-Shelf, Shared Neoantigen-Based Personal Vaccines


• Vaccine design approach for two types of personal vaccines, off-the-shelf with candidate CDx and personalized: leveraging Cancer Testis Antigens as nonmutated neoantigens
• Data reveal from phase I/II clinical trial with PolyPEPI1018 off the shelf vaccine against MSS mCRC – unprecedented immunogenicity and initial efficacy
• Improved selection of Personal Epitopes (PEPIs) that induce predictable cytotoxic T cell responses – exploring our personalised cancer vaccines proof of concept study
• How this technology leads to a shorter needle-to-needle time and a more scalable product

9:45 am An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens


• Outline a high-performing machine learning approach, trained on mass spectrometry data, that predicts naturally processed and presented antigens
• Demonstrate how the predictor is integrated with several immune parameters, such HLA binding, in a deep learning layer to predict bona fide neoantigens
• Illustrate it’s application to significantly improve the identification of neoantigen targets for personalised cancer immunotherapy

10:15 am Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working to advance cell therapies. Benchmark against the industry leaders and establish meaningful business relationships to pursue for the rest of the conference and beyond

10:45 am Morning Refreshments


Distinguishing Novel Neoantigen Discovery Tools for Development of Potent Tumorigenic Immune Responses

11:15 am Driving Antigen Discovery in Cervical Cancer


  • Evaluating how personalised genome or transcriptome sequencing information is essential for neoantigen discovery using LC-MS technology
  • RNAseq allows variant mapping and identification of cryptic antigens
  • Pathogen-driven tumours harbour a range of so far unknown targetable, tumourspecific neoantigen

11:45 am Past and future developments in the use of AI heuristics for successful neoantigen prediction


  • Overview of biological processes involved in neoantigen immunogenicity that are being approximated by using innovative computational biosimulation
  • Describing the clinical importance of increasing the True Positive Rate by using AI heuristics
  • Identification of missing datasets key to successful prediction , and which efforts are being taken in the landscape to overcome these.

12:15 pm Using Predictive Bioinformatics Algorithms to Determine Neoantigen Peptide Synthesis Difficulty & Subsequent Production Methodology

  • Raymond Miller Senior Global Product Manager, Therapeutic Materials, GenScript Biotech Corporation


  • NeoAntigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, length, and charge.
  • Leveraging extensive peptide synthesis experience GenScript has developed
  • NeoPreTM, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone.
  • NeoPreTM can then recommend the most efficient approach to successfully synthesizing peptides using one of GenScript’s many synthesis platforms
  • This presentation will highlight how NeoPreTM identifies synthesis difficulty and review successful cases of difficult neoantigen peptide synthesis from several researchers


Supercharging Induction of Anti-Tumor Response by Exploring Different Delivery Platforms for Neoantigen Vaccination

11:15 am Development of an optimized platform for production and efficacy of personalized DNA vaccines


  • Personalized cancer vaccines suffer from long lead times, high costs, and/or low immunogenicity.
  • Immunetune developed a cell-free production platform that enables rapid and affordable manufacturing of DNA vaccines for individual use.
  • Optimized vaccine design and a pyroptosis-inducing genetic adjuvant boost T cell priming and improve tumor control.

11:45 am Leveraging Onocolytic Viruses to Develop a Flexible Neoantigen Delivery Platform


  • Proprietary PeptiCRAd synergistically combine next generation oncolytic viruses with tumor associated antigens to trigger unparalleled T-cell mediated anti-tumor immune response
  • Platform-based delivery can accommodate shared tumor antigens or patient-specific neoantigens
  • Viruses are the perfect adjuvant for tumor-specific antigen delivery
  • PeptiCRAd is synergistic with standard-of-care checkpoint inhibitors

12:15 pm Towards a Flexible Peptide Based Delivery Platform for data-driven Personalized Cancer Therapy

  • Sara Mangsbo Associate Professor, Uppsala University Sweden


  • MHC/peptide off-rates can determine peptide pharmacokinetic properties, a risk for “naked” peptide-based neoantigen therapeutics
  • A flexible delivery system must provide improved stability, delivery and adjuvant capacity to peptide-based vaccines
  • The talk will address the need of a flexible and scalable platform to improve crosspresentation for the optimal CD8 T cell activation in a patient’s body and present a novel platform that achieves this goal

12:45 pm Lunch

Distinguishing Novel Neoantigen Discovery Tools for Development of Potent Tumorigenic Immune Responses

1:45 pm Identify HLA Class I and Class II specific TCRs in Pancreatic Cancer for Individualized T Cell Therapy

  • Lei Zheng Associate Professor, John Hopkins School of Medicine

2:15 pm Disease-specific Immunopeptides for Generation of Soluble TCR Therapies

2:45 pm AI in personalized cancer medicine – recent improvements and next steps

3:15 pm FlowVax: A Synthetic, Adjuvanted Microsphere Peptide Vaccine Platform

3:45 pm High throughput sequencing solutions for the quality control of innovative therapies

Optimizing Immune Priming in Neoantigen Based Cancer Vaccines for Enhanced Efficacy of Treatment

1:45 pm Intravenous vaccination improves cancer treatment efficacy


  • Vaccines based on self-assembling nanoparticles (SNAPvaxTM) enable consistent multi-antigen formulations and improved efficiency for priming T cell immunity
  • SNAPvaxTM administered intravenously (IV) provides superior efficacy by priming higher quality T cells and engaging each stage of the cancer immunity cycle
  • SNAPvaxTM is effective alone and can enhance efficacy when used in combination with complementary immunotherapies (e.g., oncolytic viruses)

2:15 pm Developing Novel Antibodies to Targeting Tumour Neoepitopes


  • Exploring a functional approach vs the classic predictive approach
  • Evaluating different techniques of measuring immunogenicity
  • Considerations towards scaling up and commercialization
  • Preliminary clinical data from trials utilizing this approach

2:45 pm Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines


  • Intratumoral administration of proinflammatory allogeneic DCs (ilixadencel) as direct immune primers.
  • Epidermal administration of leukemia-derived allogeneic DCs (DCP-001) as indirect immune primers by harnessing the immune-priming potential of alloreactive tissue-resident memory T cells.

3:15 pm Does the Exquisite Tumor-Specificity of Neoantigens Render them Excellent Targets for Bispecific Antibody Therapy of Solid Tumors?


  • Bispecific antibodies are showing great promise in B cell malignancies where specific B cell markers offer good tumor targets
  • Solid tumors have proven more challenging given lack of suitably tumor-specific targets
  • Neoantigenic HLA-peptide complexes are highly tumor-specific and may provide good targets for TCR-mimetic antibody-based bispecific approaches

3:45 pm Challenges in Peptide Manufacture Supporting Neoantigen-Derived Cancer Vaccines and How to Overcome Them

  • Alastair Hay Head of Peptide Business and Process Development, Almac Sciences


  • Challenges in enabling fast delivery of manufacturing peptides for individualised cancer vaccine therapies, within the required manufacturing controls
  • How Almac has met the demands of the clinical research community and established itself as the world leading supplier in the field of neoantigen-derived peptides through its NeoPeptide™ platform
  • Key factors that have enabled Almac to meet the manufacturing challenges

3:55 pm Afternoon Refreshments

4:15 pm Personalis® NeXT Platform® for High-Accuracy Neoantigen Prediction, Composite Biomarker Identification and Personalized Cancer Therapy Development

  • Maik Pruess Senior Field Applications Scientist, Personalis


• NEOPS™ (Neoantigen Presentation Score) combines the tumor genomic and immune-related analytics of the Personalis NeXT Platform to create a composite biomarker that can be more effective in predicting immunotherapy response than other, simpler biomarkers.

• SHERPA™ (Systematic HLA Epitope Ranking Pan Algorithm) improves neoantigen presentation prediction compared to other in silico methods, and can enable more predictive biomarkers for cancer therapy as well as facilitate the development of neoantigen-targeting, personalized cancer therapies.

• NEOPS, SHERPA, and other recent enhancements to the company’s HLA typing, HLA LOH detection and transcriptome analytics represent the latest update to the comprehensive suite of advanced analytical engines of the Personalis NeXT Platform. Utilizing an augmented exome and transcriptome-based approach, NeXT enables the simultaneous analysis of both a tumor and its immune microenvironment from a single tumor specimen to explore critical immunotherapy-related resistance mechanisms and novel composite biomarkers of response.

4:45 pm Personalised Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step


• Typical solid tumor epithelial cells display class I HLA-presented neoantigens (not class II)
• Consistent priming of strong CD8+ T cell responses to these neoantigens is likely key to effective immunotherapy
• We will show phase one clinical and immunogenicity data from a heterologous prime-boost neoantigen immunotherapy program in solid tumor patients

5:15 pm Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

5:45 pm Chair’s Closing Remarks

6:00 pm End of Day 1 of Neoantigen Summit Europe